Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies

Oxana V Galzitskaya

doi:10.3389/fnmol.2019.00319

Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies

Front Mol Neurosci. 2020 Jan 31:12:319. doi: 10.3389/fnmol.2019.00319. eCollection 2019.

Author

Oxana V Galzitskaya^{1

2}

Affiliations

¹ Laboratory of Bioinformatics and Proteomics, Institute of Protein Research, Russian Academy of Sciences, Pushchino, Russia.
² Laboratory of the Structure and Function of Muscle Proteins, Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Russia.

Abstract

Currently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers models of processes that occur during the formation of amyloid aggregates. Since this model is also characteristic of other proteins and peptides, a new potential target for drug development in the treatment of Alzheimer's disease (AD) and other proteinopathies is proposed on the basis of this model. In our opinion, it is oligomers that are promising targets for innovative developments in the treatment of these diseases.

Keywords: amyloid; drug; model; oligomer; polymorphism.